HCW Biologics CEO and 10% owner Hing Wong purchased 23,210 shares of company stock on July 29, 2026. The transaction was executed at a price of $2.59 per share. An SEC filing disclosed the purchase on August 1, 2026.
Wong has accumulated a total of 137,089 shares over the past 12 months. He has recorded zero share sales during this period.
The clinical-stage biopharmaceutical company utilizes its proprietary TOBI platform to develop novel immunotherapies. This consistent insider accumulation suggests strong executive confidence in the firm's future prospects.